[Progress in risk stratification and treatment of high-risk smoldering multiple myeloma]. [PDF]
Zhou JQ, Hao M, An G.
europepmc +1 more source
Construction of a treatment response prediction model for multiple myeloma based on multi-omics and machine learning. [PDF]
Zhou X, Gui R, Liu J, Gao M.
europepmc +1 more source
[Expression of GPRC5D in newly diagnosed patients with multiple myeloma detected by flow cytometry and its prognostic value]. [PDF]
Jin CQ, Yan F, Ma A, Xu KL, Xia JY.
europepmc +1 more source
[Clinical characteristics and survival outcomes of patients with immunoglobulin A multiple myeloma in the bortezomib era: A single-center retrospective cohort study]. [PDF]
Gao F +5 more
europepmc +1 more source
[Chinese guidelines on response assessment and minimal residual disease monitoring in multiple myeloma (2024)]. [PDF]
Multiple Myeloma Expert Committee of Chinese Society of Clinical Oncology (CSCO) +2 more
europepmc +1 more source
[Renal response and prognosis of newly diagnosed patients with multiple myeloma with renal impairment applying VRD and autologous hematopoietic stem cell transplantation]. [PDF]
Wu XY +15 more
europepmc +1 more source
[Prognostic analysis of 19 newly treated multiple myeloma patients with t(14; 16)]. [PDF]
Li Y, Liu JR, Li J, Chen WM.
europepmc +1 more source
[The Chinese clinical expert consensus for the BCMA bispecific T cell engager in the treatment of multiple myeloma (2025)]. [PDF]
Chinese Hematology Association +6 more
europepmc +1 more source

